SGMT Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fi…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data Sagimet Biosciences Inc Series A (NASDAQ:SGMT) shares rose more than 12% in pre-market trading on Wednesday following the release of 52-week results from license partner Ascletis’ Phase 3 open-label extension trial evaluating denifanstat in patients with moderate to severe acne. The trial reported a 57% treatment success rate after 52 weeks of denifanstat treatment, alongside a 72% reduction in total lesions and a 77% reduction in inflammatory lesions. | ||
 Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market Sagimet’s Denifanstat produced a 57% treatment-success rate after up to 52 weeks. | ||
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell Sagimet Biosciences (SGMT) priced an offering of about 8.8 million shares of series A common stock a | ||
 Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026. Research and development expense rose to $11.5 million from $7.2 million a year earlier as the company prepared for its Phase 3 trial, while general and administrative expense declined slightly to $4.3 million. Net loss widened to $14.0 […] | ||
 Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executive | ||
Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says Sagimet Biosciences (SGMT) is making "good progress" in advancing denifanstat as a treatment for mod | ||
 Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion Sagimet Biosciences Inc. (NASDAQ:SGMT) is one of the 10 best stocks under $10 that could triple. On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader Russell 3000 Index and the small-cap focused Russell 2000 Index, as part of the Russell Indexes reconstitution for 2026. The June index reconstitution […] | ||